The content on this site is intended for healthcare professionals only
Dr David Tweardy speaks to ecancer at the WIN 2019 Symposium in Paris about a drug program targeting STAT3, a cancer molecule involved in most cancers.
He explains that they began looking at STAT3 25 years ago as it was discovered to be a major master regulator within the cell after coming into contact with interleukin 6, a hormone that circulates upon any injury or illness.
If an injury persists and STAT3 continues to be activated then this can cause cancer.
Dr Tweardy explains that this is why molecules were developed to try and 'turn it off' and that now this is the process of trying to convert this finding into drugs.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
